NCT00219635已完成2 期
A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Flexible Dose Study To Assess The Efficacy and Safety Of Oral UK-390,957 In Men With Premature Ejaculation
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 138
- 试验地点
- 22
- 主要终点
- Assessment of efficacy and safety
研究概览
简要总结
Assessment of efficacy and safety UK-390,957
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Premature ejaculation as defined by DSM-IV
排除标准
- •History of erectile dysfunction
结局指标
主要结局
Assessment of efficacy and safety
次要结局
- Assessment of quality of sexual life
研究者
研究点 (22)
Loading locations...
相似试验
已完成
2 期
Assessment Of Efficacy and Safety Of UK-390,957 In Men With Premature EjaculationEjaculationNCT00219583Pfizer460
已完成
2 期
To Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH) .Non-Alcoholic Steatohepatitis (NASH)NCT06168383Haisco Pharmaceutical Group Co., Ltd.186
终止
2 期
Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high AsthmaAsthmaNCT05935332RAPT Therapeutics, Inc.38
已完成
2 期
Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 DiabetesNew Onset Type-1 DiabetesNCT02005848Kamada, Ltd.70
终止
2 期
A Study of ATL1102 or Placebo in Participants with Non-ambulatory Duchenne Muscular DystrophyDuchenne Muscular DystrophyNCT05938023Percheron Therapeutics48